On March 18, 2026, MiniMed Group, Inc., a subsidiary of Medtronic plc, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the MiniMed Flex™, a next-generation discreet, smartphone-controlled insulin pump. This clearance was achieved several months ahead of expectations, allowing for earlier commercialization of this significant product. The development of the MiniMed Flex was partially funded by Blackstone Life Sciences Advisors L.L.C., which will receive royalties based on net sales following the product's launch. Medtronic anticipates recognizing a one-time charge of $157 million in the fourth quarter of fiscal year 2026 due to future payments owed to Blackstone, which is expected to impact earnings per share (EPS) by $0.08. Additionally, the timing of MiniMed's initial public offering (IPO) is projected to dilute Medtronic's EPS by approximately $0.04 in the same quarter. Consequently, Medtronic has revised its non-GAAP EPS guidance for fiscal year 2026 to a range of $5.50 to $5.54, down from the previous guidance of $5.62 to $5.66. However, the company's outlook for fiscal year 2027 remains unchanged, with expectations of high single-digit EPS growth. These developments reflect both operational execution and strategic adjustments in response to market conditions and product timelines.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.